This clinical trial is focused on studying the effects of a treatment for patients who have experienced a cardiac arrest, specifically those with a type of irregular heart rhythm known as ventricular fibrillation. The treatment being tested is a medication called landiolol hydrochloride, which is a type of drug known as a beta-blocker. Beta-blockers are commonly used to manage heart conditions by slowing down the heart rate and reducing blood pressure. In this study, landiolol hydrochloride is being compared to a placebo to see if it can help improve the chances of the heart starting to beat on its own again after a cardiac arrest.

The purpose of the study is to find out if adding landiolol hydrochloride to the standard treatment for cardiac arrest can decrease the time it takes for the heart to achieve a sustained return of spontaneous circulation (sROSC), which means the heart starts beating effectively on its own. Participants in the study will receive either the landiolol hydrochloride or a placebo through an intravenous injection, which means the medication is given directly into a vein. The study will monitor how quickly the heart starts beating again and will also look at other outcomes, such as survival after 24 hours and the patient’s neurological condition.

In addition to landiolol hydrochloride, the study involves the use of sodium chloride solution, which is a common fluid used in medical settings to help deliver medications intravenously. The study is designed to be double-blind, meaning neither the participants nor the researchers know who is receiving the actual medication or the placebo, ensuring unbiased results. The trial aims to provide valuable information on whether landiolol hydrochloride can be an effective addition to the treatment of cardiac arrest, potentially improving outcomes for patients experiencing this life-threatening condition.